Angiodynamics Inc: Form 10-Q for the period ended Feb 28, 2023
Filed with the SEC on Mar 31, 2023 and accepted by EDGAR at Mar 31, 2023, 14:32 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2023-02-28. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2022-12-01 to 2023-02-28 | $80.7m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months2022-06-01 to 2023-02-28 | $247.7m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2022-12-01 to 2023-02-28 | $40.2m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months2022-06-01 to 2023-02-28 | $119.8m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months2022-12-01 to 2023-02-28 | $40.5m | us-gaap:GrossProfit |
| Gross profit | 9 months2022-06-01 to 2023-02-28 | $127.9m | us-gaap:GrossProfit |
| Research and development | 3 months2022-12-01 to 2023-02-28 | $6.9m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2022-06-01 to 2023-02-28 | $22.0m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2022-12-01 to 2023-02-28 | −$8.9m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2022-06-01 to 2023-02-28 | −$30.3m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2022-12-01 to 2023-02-28 | $736.0k | us-gaap:InterestExpense |
| Interest expense | 9 months2022-06-01 to 2023-02-28 | $1.8m | us-gaap:InterestExpense |
| Income tax | 3 months2022-12-01 to 2023-02-28 | −$179.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2022-06-01 to 2023-02-28 | −$1.6m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2022-12-01 to 2023-02-28 | −$9.5m | us-gaap:NetIncomeLoss |
| Net income | 9 months2022-06-01 to 2023-02-28 | −$31.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2022-12-01 to 2023-02-28 | −$0.24 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2022-06-01 to 2023-02-28 | −$0.79 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2022-12-01 to 2023-02-28 | −$0.24 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2022-06-01 to 2023-02-28 | −$0.79 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2022-12-01 to 2023-02-28 | 39,509,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2022-06-01 to 2023-02-28 | 39,436,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2022-06-01 to 2023-02-28 | −$15.9m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2022-06-01 to 2023-02-28 | $2.8m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2023-02-28 | $30.1m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2023-02-28 | $152.6m | us-gaap:AssetsCurrent |
| Total assets | At period end2023-02-28 | $542.8m | us-gaap:Assets |
| Current liabilities | At period end2023-02-28 | $69.6m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2023-02-28 | $145.2m | us-gaap:Liabilities |
| Long-term debt | At period end2023-02-28 | $49.8m | us-gaap:LongTermDebt |
| Shareholders' equity | At period end2023-02-28 | $397.7m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001628280-23-010093. Last ingested by Listed: Nov 4, 2026, 20:24 ET. Listed shows no prices and gives no investment advice.